These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

324 related items for PubMed ID: 26827607

  • 1. Personalized Pharmacoperones for Lysosomal Storage Disorder: Approach for Next-Generation Treatment.
    Haneef SA, Doss CG.
    Adv Protein Chem Struct Biol; 2016; 102():225-65. PubMed ID: 26827607
    [Abstract] [Full Text] [Related]

  • 2. Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders.
    Parenti G, Andria G, Valenzano KJ.
    Mol Ther; 2015 Jul; 23(7):1138-1148. PubMed ID: 25881001
    [Abstract] [Full Text] [Related]

  • 3. Recent developments in therapeutic approaches for lysosomal storage diseases.
    Urbanelli L, Magini A, Polchi A, Polidoro M, Emiliani C.
    Recent Pat CNS Drug Discov; 2011 Jan; 6(1):1-19. PubMed ID: 21073432
    [Abstract] [Full Text] [Related]

  • 4. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics.
    Parenti G.
    EMBO Mol Med; 2009 Aug; 1(5):268-79. PubMed ID: 20049730
    [Abstract] [Full Text] [Related]

  • 5. New strategies for the treatment of lysosomal storage diseases (review).
    Parenti G, Pignata C, Vajro P, Salerno M.
    Int J Mol Med; 2013 Jan; 31(1):11-20. PubMed ID: 23165354
    [Abstract] [Full Text] [Related]

  • 6. Enzyme enhancement therapeutics for lysosomal storage diseases: Current status and perspective.
    Thomas R, Kermode AR.
    Mol Genet Metab; 2019 Feb; 126(2):83-97. PubMed ID: 30528228
    [Abstract] [Full Text] [Related]

  • 7. Pharmacological chaperones for enzyme enhancement therapy in genetic diseases.
    Aymami J, Barril X, Rodríguez-Pascau L, Martinell M.
    Pharm Pat Anal; 2013 Jan; 2(1):109-24. PubMed ID: 24236974
    [Abstract] [Full Text] [Related]

  • 8. Treatment of lysosomal storage diseases: recent patents and future strategies.
    Ortolano S, Viéitez I, Navarro C, Spuch C.
    Recent Pat Endocr Metab Immune Drug Discov; 2014 Jan; 8(1):9-25. PubMed ID: 24433521
    [Abstract] [Full Text] [Related]

  • 9. Oral small molecule therapy for lysosomal storage diseases.
    Weinreb NJ.
    Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():77-90. PubMed ID: 24380126
    [Abstract] [Full Text] [Related]

  • 10. A chaperone-mediated approach to enzyme enhancement as a therapeutic option for the lysosomal storage disorders.
    Pastores GM, Sathe S.
    Drugs R D; 2006 Nov; 7(6):339-48. PubMed ID: 17073517
    [Abstract] [Full Text] [Related]

  • 11. Therapeutic approaches for lysosomal storage diseases: a patent update.
    Urbanelli L, Sagini K, Polidoro M, Brozzi A, Magini A, Emiliani C.
    Recent Pat CNS Drug Discov; 2013 Aug; 8(2):91-109. PubMed ID: 23713988
    [Abstract] [Full Text] [Related]

  • 12. Treatment strategies for lysosomal storage disorders.
    Beck M.
    Dev Med Child Neurol; 2018 Jan; 60(1):13-18. PubMed ID: 29090451
    [Abstract] [Full Text] [Related]

  • 13. Enzyme Replacement Therapy: A Review and Its Role in Treating Lysosomal Storage Diseases.
    Li M.
    Pediatr Ann; 2018 May 01; 47(5):e191-e197. PubMed ID: 29750286
    [Abstract] [Full Text] [Related]

  • 14. Combination Therapies for Lysosomal Storage Diseases: A Complex Answer to a Simple Problem.
    Macauley SL.
    Pediatr Endocrinol Rev; 2016 Jun 01; 13 Suppl 1(Suppl 1):639-48. PubMed ID: 27491211
    [Abstract] [Full Text] [Related]

  • 15. Therapeutic Role of Pharmacological Chaperones in Lysosomal Storage Disorders: A Review of the Evidence and Informed Approach to Reclassification.
    Keyzor I, Shohet S, Castelli J, Sitaraman S, Veleva-Rotse B, Weimer JM, Fox B, Willer T, Tuske S, Crathorne L, Belzar KJ.
    Biomolecules; 2023 Aug 07; 13(8):. PubMed ID: 37627292
    [Abstract] [Full Text] [Related]

  • 16. Emptying the stores: lysosomal diseases and therapeutic strategies.
    Platt FM.
    Nat Rev Drug Discov; 2018 Feb 07; 17(2):133-150. PubMed ID: 29147032
    [Abstract] [Full Text] [Related]

  • 17. Treatment options for lysosomal storage disorders: developing insights.
    van Gelder CM, Vollebregt AA, Plug I, van der Ploeg AT, Reuser AJ.
    Expert Opin Pharmacother; 2012 Nov 07; 13(16):2281-99. PubMed ID: 23009070
    [Abstract] [Full Text] [Related]

  • 18. Lysosomal storage diseases: current therapies and future alternatives.
    Leal AF, Espejo-Mojica AJ, Sánchez OF, Ramírez CM, Reyes LH, Cruz JC, Alméciga-Díaz CJ.
    J Mol Med (Berl); 2020 Jul 07; 98(7):931-946. PubMed ID: 32529345
    [Abstract] [Full Text] [Related]

  • 19. Treatments for lysosomal storage disorders.
    Lachmann R.
    Biochem Soc Trans; 2010 Dec 07; 38(6):1465-8. PubMed ID: 21118108
    [Abstract] [Full Text] [Related]

  • 20. Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders.
    Valenzano KJ, Khanna R, Powe AC, Boyd R, Lee G, Flanagan JJ, Benjamin ER.
    Assay Drug Dev Technol; 2011 Jun 07; 9(3):213-35. PubMed ID: 21612550
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.